Michael Mannstadt, MD is Chief of the Endocrine Unit at the Massachusetts General Hospital and Associate Professor in Medicine at Harvard Medical School. His clinical and research interests focus on diseases of the parathyroid glands. He is particularly interested in hypoparathyroidism, and his research spans the basic, translational, and clinical realms of the disease. He is the principal investigator of an NIH grant for the development of a long-acting PTH, and the lead author of the phase 3 clinical trial of PTH(1-84) in hypoparathyroidism. Dr. Mannstadt also hopes that the Natpara recall is soon over. He is a medical advisor for the Hypoparathyroid Association and a frequent faculty participant at their annual patient meetings.